Skip to main content
SpringerLink
Log in

Pharmacogenomics in Acute Myeloid Leukemia

  • Chapter
  • First Online:
Omics for Personalized Medicine

Abstract

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells. In AML, the bone marrow makes many immature cells called blasts, which do not mature and cannot fight infections. AML is a heterogeneous neoplasm with several pathological, genetic, and molecular subtypes. Combinations of various doses and schedules of drugs have been the majority of treatment for all types of AMLs in adult patients. However, not all patients have the same response to these treatments, some of which are adverse responses that are potentially life threatening. Because interindividual responses to AML medications can vary considerably, the potential for genetic contributions to variable drug responses is significant. The pharmacogenomics approach tries to find prognostic and predictive biomarkers permitting to identify patients who could benefit from a particular treatment or those exhibiting higher risks of toxicity. Pharmacogenomics is a rapidly improving science with the potential to revolutionize drug discovery/development and offers one possibility for rationalizing therapy/dose selection. It combines many different fields such as genetics, genomics, molecular biology, pharmacology, pharmaceutics, and population biology. This chapter focuses on treatment of AML, genetic and clinical prognostic markers, and recent advances in the field of pharmacogenomics in AML.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325(3):859–868

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30(1):41–47

    Article  CAS  PubMed  Google Scholar 

  • Austin H, Delzell E, Cole P (1988) Benzene and leukemia. A review of the literature and a risk assessment. Am J Epidemiol 127(3):419–439

    CAS  PubMed  Google Scholar 

  • Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U (2006) Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 81(3):162–170

    Article  CAS  PubMed  Google Scholar 

  • Badrul Hisam HR, Ros M, Aziz A, Narazah M (2006) Screening for 3435C>T and 2677G>T/A polymorphisms of multi-drug resistance (MDR1) gene in Malay patients with leukemia. Malays J Biochem Mol Biol 14(1)

    Google Scholar 

  • Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297

    Article  CAS  PubMed  Google Scholar 

  • Bartsocas CS, Loukopoulos D (1992) Bloom’s syndrome: incidence, age of onset, and types of leukemia in the Bloom’s syndrome registry. In: Bartsocas CS, Loukopoulos D (eds) Genetics in hematologic disorders. Hemisphere, Washington, DC, pp 241–258

    Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451–458

    Article  CAS  PubMed  Google Scholar 

  • Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A, Vitols S (2010) Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett 4(4):228–232

    Article  CAS  PubMed  Google Scholar 

  • Brockmoller J, Cascorbi I, Kerb R, Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56(17):3915–3925

    CAS  PubMed  Google Scholar 

  • Burcu M, O’Loughlin KL, Ford LA, Baer MR (2008) Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 22(11):2110–2115

    Article  CAS  PubMed  Google Scholar 

  • Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336

    Article  CAS  PubMed  Google Scholar 

  • Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99(24):15524–15529

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chang P, Kang M, Xiao A, Chang J, Feusner J, Buffler P, Wiemels J (2010) FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer 10:513

    Article  PubMed Central  PubMed  Google Scholar 

  • Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102(39):13944–13949

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Davies SM, Robison LL, Buckley JD, Radloff GA, Ross JA, Perentesis JP (2000) Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children’s Cancer Group study. Cancer Epidemiol Biomarkers Prev 9(6):563–566

    CAS  PubMed  Google Scholar 

  • Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA, Ross JA, Perentesis JP (2001) Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19(5):1279–1287

    PubMed  Google Scholar 

  • De Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink MM, Kaspers GJ, Zwaan CM, Kamps WA, Lowenberg B, de Bont ES (2010) High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116(10):1747–1754

    Article  PubMed  Google Scholar 

  • Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740–3746

    Article  PubMed  Google Scholar 

  • Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474

    Article  PubMed  Google Scholar 

  • Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122(4):904–915

    Article  CAS  PubMed  Google Scholar 

  • Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, Seeber S, Moritz T, Flasshove M (2007) Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 117(1):8–15

    Article  CAS  PubMed  Google Scholar 

  • Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894–1907

    Article  PubMed  Google Scholar 

  • Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439):487–491

    Article  CAS  PubMed  Google Scholar 

  • Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266

    Article  CAS  PubMed  Google Scholar 

  • Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS (2005) Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15(3):331–341

    Article  CAS  PubMed  Google Scholar 

  • Foran JM (2010) New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010:47–55

    Article  PubMed  Google Scholar 

  • Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26(7):621–629

    Article  CAS  PubMed  Google Scholar 

  • Gradhand U, Kim RB (2008) Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40(2):317–354

    Article  CAS  PubMed  Google Scholar 

  • Green H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R, Paul C, Nahi H (2012) Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J 12(2):111–118

    Article  CAS  PubMed  Google Scholar 

  • Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7):2322–2333

    CAS  PubMed  Google Scholar 

  • Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365

    Article  CAS  PubMed  Google Scholar 

  • Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6(7):493–505

    Article  CAS  PubMed  Google Scholar 

  • Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, Schoch C (2005) Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106(4):1189–1198

    Article  CAS  PubMed  Google Scholar 

  • Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, De Vos J, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R (2010) Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 28(15):2529–2537

    Article  CAS  PubMed  Google Scholar 

  • Hirose M, Hosoi E, Hamano S, Jalili A (2003) Multidrug resistance in hematological malignancy. J Med Invest 50(3–4):126–135

    PubMed  Google Scholar 

  • Horwitz M (1997) The genetics of familial leukemia. Leukemia 11(8):1347–1359

    Article  CAS  PubMed  Google Scholar 

  • Huang Y, Sadee W (2006) Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239(2):168–182

    Article  CAS  PubMed  Google Scholar 

  • Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62(17):4955–4962

    CAS  PubMed  Google Scholar 

  • Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355(12):1253–1261

    Article  CAS  PubMed  Google Scholar 

  • Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Hoglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113(18):4179–4187

    Article  CAS  PubMed  Google Scholar 

  • Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179–198

    Article  CAS  PubMed  Google Scholar 

  • Kim DH, Park JY, Sohn SK, Lee NY, Suh JS, Lee KB (2006a) The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation. Haematologica 91(6):848–851

    CAS  PubMed  Google Scholar 

  • Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB (2006b) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118(9):2195–2201

    Article  CAS  PubMed  Google Scholar 

  • Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24):5089–5102

    Article  CAS  PubMed  Google Scholar 

  • Lane SW, Scadden DT, Gilliland DG (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114(6):1150–1157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3):1086–1099

    CAS  PubMed  Google Scholar 

  • Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C (2005) CEBPA point mutations in hematological malignancies. Leukemia 19(3):329–334

    Article  CAS  PubMed  Google Scholar 

  • Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19(1):47–84

    CAS  PubMed  Google Scholar 

  • Lindstrom MS (2011) NPM1/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int 2011:195209

    PubMed Central  PubMed  Google Scholar 

  • Liotta L, Petricoin E (2000) Molecular profiling of human cancer. Nat Rev Genet 1(1):48–56

    Article  CAS  PubMed  Google Scholar 

  • List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87(6):2464–2469

    CAS  PubMed  Google Scholar 

  • Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA (2001) Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 22(7):1053–1060

    Article  CAS  PubMed  Google Scholar 

  • Michael M, Doherty MM (2005) Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 23(1):205–229

    Article  CAS  PubMed  Google Scholar 

  • Miller RW (1971) Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960–67. J Natl Cancer Inst 46(1):203–209

    CAS  PubMed  Google Scholar 

  • Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10(3):399–416

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mrozek K, Heerema NA, Bloomfield CD (2004) Cyto-genetics in acute leukemia. Blood Rev 18(2):115–136

    Article  PubMed  Google Scholar 

  • Mrozek K, Dohner H, Bloomfield CD (2007) Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 14(2):106–114

    Article  CAS  PubMed  Google Scholar 

  • Niedzielska E, Chybicka A (2011) Risk of recurrence of acute leukemia in children depending on the polymorphism for TPMT, CYP2C9 and CYP2C19. Onkol Pol 14(2):68–70

    Google Scholar 

  • Peng Y, Feng Q, Wilk D, Adjei AA, Salavaggione OE, Weinshilboum RM, Yee VC (2008) Structural basis of substrate recognition in thiopurine s-methyltransferase. Biochemistry 47(23):6216–6225

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100(8):2717–2723

    Article  CAS  PubMed  Google Scholar 

  • Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR (2009) Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 106(31):12944–12949

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Relling MV, Dervieux T (2001) Pharmacogenetics and cancer therapy. Nat Rev Cancer 1(2):99–108

    Article  CAS  PubMed  Google Scholar 

  • Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26(1):39–57

    Article  CAS  PubMed  Google Scholar 

  • Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61(1):3–13

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N (2011) VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol 80(2):241–256

    Article  PubMed  Google Scholar 

  • Rollinson S, Roddam P, Kane E, Roman E, Cartwright R, Jack A, Morgan GJ (2000) Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis 21(1):43–47

    Article  CAS  PubMed  Google Scholar 

  • Rukov JL, Vinther J, Shomron N (2011) Pharmacogenomics genes show varying perceptibility to microRNA regulation. Pharmacogenet Genomics 21(5):251–262

    Article  CAS  PubMed  Google Scholar 

  • Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409(6822):928–933

    Article  CAS  PubMed  Google Scholar 

  • Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114(11):2220–2231

    Article  CAS  PubMed  Google Scholar 

  • Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A (2005) Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24(53):7902–7912

    Article  CAS  PubMed  Google Scholar 

  • Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5(9):1048–1051

    Article  CAS  PubMed  Google Scholar 

  • Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ (2004) Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14(11):759–768

    Article  CAS  PubMed  Google Scholar 

  • Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669–3676

    Article  CAS  PubMed  Google Scholar 

  • Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G (2001) Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 22(1):67–72

    Article  CAS  PubMed  Google Scholar 

  • Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3(9):650–665

    Article  CAS  PubMed  Google Scholar 

  • Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD (2004) PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol 83(Suppl 1):S89–S90

    PubMed  Google Scholar 

  • Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011–4020

    Article  CAS  PubMed  Google Scholar 

  • van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJ, Pieters R, Sonneveld P (2001) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97(11):3605–3611

    Article  PubMed  Google Scholar 

  • van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Muller M, Vellenga E (1998) Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 4(7):1727–1736

    PubMed  Google Scholar 

  • van der Kolk DM, de Vries EG, Muller M, Vellenga E (2002) The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43(4):685–701

    Article  PubMed  Google Scholar 

  • Van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536

    Article  Google Scholar 

  • Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P (2012) Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol 68(12):1577–1586

    Article  CAS  PubMed  Google Scholar 

  • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951

    Article  CAS  PubMed  Google Scholar 

  • Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM (2000) High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 96(4):1517–1524

    CAS  PubMed  Google Scholar 

  • Voso MT, D’Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P, Latagliata R, Lo-Coco F, Rutella S, Pagano L, Hohaus S, Leone G (2002) Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100(8):2703–2707

    Article  CAS  PubMed  Google Scholar 

  • Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O’Gara BP, Bloomfield CD, Mrozek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ (2009) Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 106(31):12950–12955

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC, Chen PM (1997) High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin’s lymphoma. Jpn J Clin Oncol 27(3):154–157

    Article  CAS  PubMed  Google Scholar 

  • Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19(6):670–686

    CAS  PubMed  Google Scholar 

  • Wiernik PH (1997) Leukemias and plasma cell myeloma. Cancer Chemother Biol Response Modif 17:390–407

    CAS  PubMed  Google Scholar 

  • Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, Maeba H, Ito T, Sasaki T, Koizumi S (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13(1):29–38

    Article  CAS  PubMed  Google Scholar 

  • Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94(2):569–574

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhong Y, Chen B, Feng J, Cheng L, Li Y, Qian J, Ding J, Gao F, Xia G, Chen N, Lu Z (2010) The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leuk Lymphoma 51(6):1115–1120

    Article  CAS  PubMed  Google Scholar 

  • Zipursky A, Poon A, Doyle J (1992) Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 9(2):139–149

    Article  CAS  PubMed  Google Scholar 

  • Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG, Yanes DA, McConnell KK, Mao C, Kalu C, Zhang X, Jarjoura D, Dorrance AM, Heerema NA, Lee BH, Huang G, Marcucci G, Caligiuri MA (2012) Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 120(5):1130–1136

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Genetics, Faculty of Medicine, Turgut Ozal University, Ankara, Turkey

    Omer Faruk Hatipoglu, Onur Bender, Esra Gunduz & Mehmet Gunduz

Authors
  1. Omer Faruk Hatipoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Onur Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esra Gunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Gunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Gunduz .

Editor information

Editors and Affiliations

  1. Centre for Genomics & Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, West Bengal, India

    Debmalya Barh

  2. Institute of Life Sciences, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad University, Ahmedabad, Gujarat, India

    Dipali Dhawan

  3. Policy Centre for Biomedical Research, Translational Health Science and Technology Institute (Department of Biotechnology Institute, Government of India), Office @ National Institute of Immunology, New Delhi, India

    Nirmal Kumar Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer India

About this chapter

Cite this chapter

Hatipoglu, O.F., Bender, O., Gunduz, E., Gunduz, M. (2013). Pharmacogenomics in Acute Myeloid Leukemia. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_12

Download citation

Publish with us

Policies and ethics

Search

Navigation